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Executive Summary
The high rate of opioid misusei and subsequent addiction is an ongoing national and local public
health crisis. Despite numerous statewide efforts to reduce rates of opioid prescribing, prevent
diversion, and increase access to treatment for opioid use disorder (OUD), the most recent data
available for the state of Maine still shows the incidence of opioid-related overdoses and deaths
increasing.
Grantee
While there are numerous strategies to address this multi-faceted issue,
one evidence-based strategy to address the opioid epidemic is the
implementation of Medication-Assisted Treatment (MAT) within primary
care settings. MAT combines the use of behavioral therapy with medication.
For OUD the medication is buprenorphine (common brand names
Suboxone or Subutex). Primary care, while often involved in the initial
prescribing of opioids, is also a forward facing component of health care
that has many opportunities to interface with individuals with OUD and
provide an opportunity for them to enter treatment. However,
implementing MAT within busy primary care settings can be challenging
due to numerous barriers at the patient, provider, and practice levels.

Program Overview
The Maine Health Access Foundation (MeHAF) is currently providing funds
to expand access to MAT within primary care practices for medically
underserved individuals with OUD. In this initiative, the Addiction Care
Program, funds have been distributed to ten grantee organizations – four
are focusing on creating new capacity for MAT and six are focusing on
expanding current capacity for MAT. The initiative is two years (April 2017
– March 2019) and the structure of the Addiction Care Program allows
grantee organizations to learn from each other and share lessons learned.
As part of the Addiction Care Program, MeHAF has contracted with Quality
Counts (QC) to provide training, education, and technical assistance to
support grantee organizations, both individually and as a cohort. In
addition, QC has sub-contracted with Eric Haram, LADC of Haram
Consulting, Maine Behavioral Healthcare, for the services of Mary Jean
Mork, LCSW, and Maine Medical Association, principally Gordon Smith,
Esq., to provide specialized assistance in the areas of integrated treatment
models for OUD, billing/coding, and public policy, respectively. As grantee
organizations move into the second year, they will begin to operationalize
and refine workflows, processes, and protocols. Through ongoing technical
assistance and lesson sharing, grantee organizations will ultimately move
implementing MAT services for underserved individuals in the state.

Organizations
Planning Grants
LincolnHealth
Lincoln County
Kennebec Behavioral
Health
Somerset County
Tri-County Mental Health
Services
Androscoggin County
York H0spital
York County
Implementation Grants
Amistad
Cumberland & York
Counties
Health Access Network
Penobscot County
Healthy Acadia
Hancock and Washington
Counties
Healthy Community
Coalition
Franklin and Oxford
Counties
MaineGeneral
Kennebec, Somerset, and
Sagadahoc Counties
Penobscot Community
Health Care
Penobscot, Somerset, and
Waldo Counties

towards expanding and

i

Throughout this document, the expression “opioid misuse” refers to the use of opioids in a manner, situation, amount or
frequency that can cause harm to the substance user or to those around them. Prescription drug misuse refers to the use of a
drug in any way a doctor did not direct an individual to use it. (Taken from Facing Addiction in America: The Surgeon General’s
Report on Alcohol, Drugs, and Health. (2016)). Glossary p.3-4. U.S. Department of Health and Human Services.)
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Medication-Assisted Treatment (MAT)
At a Glance
What is MAT?
MAT is an evidence-based path of recovery from
substance use disorders facilitated by medically
monitored pharmacological agents approved by the
FDA. For opioid use disorder, these medications
include methadone, naltrexone, and buprenorphine
(common brand names: Suboxone and Subutex).
MAT is the combination of behavioral therapy with
medication that is effective for many, but not all
individuals.
Who can provide MAT?
In Maine, Physicians (MD, DO), nurse practitioners
(NP), and physician assistants (PA) can prescribe the
medication(s) associated with MAT for opioid use
disorder. To prescribe buprenorphine, providers
must take additional training and receive a waiver
from the federal government (X-waiver). The
provider works with the patient and with behavioral
health professionals to provide comprehensive care
for the person receiving MAT.
What type of training is required to provide MAT?
Physicians are required to complete an eight-hour
training to qualify for a waiver to prescribe and
dispense buprenorphine. Nurse practitioners and
physician assistants are required to complete 24
hours of training, including the initial eight-hour MAT
training for physicians.
Who is a good candidate for MAT?
Per guidance from the U.S. Substance Abuse and
Mental Health Services Agency (SAMHSA), a good
candidate for MAT for opioid use disorder:
 Has an official diagnosis of an opioid use
disorder.
 Is willing to fully comply with prescribing
instructions.
 Lacks physical health issues that the
medication could possibly exacerbate.
 Is fully educated on alternative options.
For more information on MAT:
https://www.samhsa.gov/medication-assistedtreatment

ii

The Muskie School of Public Service at the University of
Southern Maine (Muskie) was contracted by MeHAF to
conduct an independent evaluation of the
implementation and effectiveness of the Addiction Care
Program. The program evaluation is designed to inform
current and future planning activities; guide the
implementation and refinement of the intervention
strategies; provide ongoing feedback to grantee
organizations on improvements to access and delivery
of MAT in their region; and offer a summative
assessment of the implementation experience and
success of the intervention strategies. The Interim
Evaluation Report produced by Muskie discusses
findings to date in more detail.
Muskie utilized a mixed-methods design, including the
collection of both quantitative (administrative, clinical,
and survey data) and qualitative data (provider
interviews and patient focus groups), to document the
implementation
environment;
examine
factors
impacting availability and access to MAT; and evaluate
grantee strategies and whether and/or how these
approaches reduce barriers to access to treatment and
recovery supports for individuals with OUD. The
evaluation was designed to look at implementation
strategies through the lens of external and internal
implementation environments.ii

Implementation Environments
External: Currently there is a growing awareness and
readiness in Maine to develop strategies to overcome
known barriers to implementing MAT programs,
including limited infrastructure, public policies,
insufficient reimbursement, and limited financial
resources. The work being carried out by the Addiction
Care Program grantee organizations aligns and expands
upon existing state and local efforts to increase capacity
in the state to prevent and treat OUD.

Examples of external implementation environmental factors include infrastructure, public policies, financial resources, and
reimbursement issues. Examples of internal implementation environmental factors includes organizational cultures,
organizational capacity, and provider motivation and readiness.
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Internal: Data collected thus far indicates grantee organizations, as well as most providers, are
motivated and ready to implement MAT within their organizations. Correspondingly, the overall
organizational culture of the grantee organizations is a facilitator in the implementation of clinical
interventions.

Grantee Milestones
During the first year of the grant, Addiction Care Program grantee organizations engaged in a substantial
effort to provide training and education to a broad group of stakeholders that included executives,
providers, administrative staff, and community partners. Sites reported holding 320 training/education
sessions covering a broad range of relevant topics. On average, trainings lasted one to two hours and a
total of 3,007 attendees were recorded across the education and training sessions held by grantee
organizations. Sessions covered a wide variety of service delivery and implementation topics such as:
screening and diagnosis for OUD, chronic pain management, implementing MAT workflows, and patient
engagement strategies. A total of 56 individuals received training in MAT. Twenty-five of these
individuals went on to complete the required federal training program necessary to prescribe or
dispense buprenorphine, greatly increasing the capacity of Addiction Care Program grantee
organizations to deliver MAT in their targeted geographic areas.
The number of providers delivering MAT across the six implementation grantee organizations nearly
tripled from 27 to 73 providers, this
represents a 170% increase in the
number of prescribers. There was a
corresponding increase in the
number of patients receiving MAT
services at program sites. Between
October and March of 2017 there was
a 75% increase in the number of
patients receiving MAT. Of the 230
patients who were referred for
induction, eighty percent were
induced on buprenorphine. This high
induction rate indicates that most
referrals to MAT were appropriate,
and that, patients did not face major
barriers in starting treatment. For
example, it is likely that scheduling
the first therapy session and
appointment with their PCP was amenable for the patient and increased their chances of starting MAT.
In addition to increasing the number of patients seen and induced, grantee organizations also
significantly increased the number of behavioral health referrals at their sites. Of the over 900 patients
referred to behavioral health services, 94% attended their first behavioral health visit.
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Successful Strategies
Administrative and provider interview data collected over the course of the first year of the Addiction
Care Program provides key insights into the successful planning and implementation strategies used by
grantee organizations. Grantee organizations indicated that collaboration and stakeholder engagement
have been critical to informing systems of care and establishing the partnerships necessary to provide
comprehensive MAT programs that include treatment, social services, and recovery supports. Both
providers and patients agree that MAT services provided in environments that are co-located with
physical and behavioral health care greatly reduces barriers to access and facilitates a holistic approach
to addressing the complex physical and behavioral health care needs of individuals with OUD. A grantee
organization without co-located services employed universal releases to increase low barrier access to
treatment while at the same time providing for improved communication and care coordination across
partner agencies.

Challenges and Opportunities for Change
The Addiction Care Program is being implemented at a time when there is considerable interest in
developing strategies to expand the state’s treatment infrastructure to address the opioid epidemic.
However, despite support at both the governmental and health systems levels, substantial barriers to
increasing access to MAT remain. Over the course of the first year of the Addiction Care Program,
grantee organizations identified a number of challenges to expanding access to MAT in primary care
settings. These challenges include the time and effort to manage and sustain collaborations across
multiple sectors of care; reimbursement and payment for services; external rules and regulations that
hinder process and capacity building; staff turnover that diminishes MAT capacity; inclusion of persons
in recovery and patients within the collaborative process (including within peer recovery support
networks); and lack of infrastructure to support real time data tracking and monitoring of MAT patient
panels. Addiction Care Program grantee organizations are utilizing the technical assistance and
resources provided by the Addiction Care Program to lay the foundation necessary to overcome
identified barriers and expand access to evidence-based treatment programs within their service areas.

Key Findings
After the first year of the Addiction Care Program, the overarching key findings were summarized into
the following themes:
Payment/Reimbursement for Services: Resources are one of the greatest barriers to implementing
and sustaining MAT programs in a primary care setting. Some treatment programs and insurance
companies have placed limits and regulations on who can be prescribed MAT and for what duration.
These policies are intended to ensure that MAT is the best course of treatment for patients, yet they
often make it harder for practices to offer patient-centered services.1 Practices often lack the necessary
financial resources as well as the human capital, time and organizational capacity to expand and/or
sustain MAT programs without external support and funding. It is evident that there continues to be a
need to advocate for policies that cover the cost of MAT services and ongoing supports as well as
financial and technical resources to make implementing and sustaining MAT programs accessible to
practices and providers.
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Low Barrier Access to Treatment: Creating low barrier access to MAT is a critical component to
ensuring treatment initiation and engagement for high-risk patients.2 Effective systems must ensure that
individuals with OUD needing treatment will be identified, assessed, and receive treatment, either
directly or through appropriate referral, no matter where he or she enters the realm of services.3
Establishing clinical-community linkages is essential for referral, assessment and treatment programs
and policies that are consistent with a “no wrong door” policy. Programs that reduce barriers to
accessing care and treatment, including low barrier access to detoxification services, are essential and
help avoid interruptions in continuity of care.
Patient-Centered Approach: There is a continued need for grantee organizations to focus on creating
treatment protocols and policies that include interventions specific to the tasks and challenges faced by
patients at each stage of treatment, maintenance and recovery. Common challenges include: time
commitments for appointments which lead to increased needs for childcare or time out of work, costs
of treatment and medication, inflexible treatment program policies, lack of awareness of available
resources, and inadequate insurance coverage. Regularly assessing patient feedback (e.g. having
treatment options) and utilizing that information to refine program requirements to meet the unique
needs of participants will promote treatment engagement and reinforce long-term participation in
maintenance and recovery activities.
Information for Patients and Families: While creating the infrastructure to support MAT in primary
care practices is paramount, awareness of OUD, available treatment options, and community supports
for individuals and families affected by substance use disorder remains a challenge, particularly in rural
communities. Future efforts could include working on communications plans and public awareness
outreach within Maine communities.
Stigma: The stigma associated with opioid use is a major barrier for providers of MAT as well as patients
in treatment and recovery. Health-related stigma is often described as a socio-cultural process in which
social groups are devalued, rejected and excluded on the basis of a socially discredited health condition.4
Stigma remains a major barrier to accessing treatment for OUD. Patients reported that stigma related
to their OUD adversely impacted many domains of their life such as: treatment engagement,
employment, housing, and social relationships. In addition, patients reported feeling stigma from family
and friends, providers, pharmacists, and from members of their communities. Moreover, providers
reported that stigma among medical providers and staff often compounds the challenges associated
with the expansion of MAT services. There continues to be a need for training, education and outreach
to address stigma associated with OUD and MAT; this training should be targeted at community
members, health care professionals, individuals with OUD, and the recovery community.
Auxiliary Recovery Supports: Auxiliary recovery supports including safe housing, food security, and
transportation are crucial elements of patient recovery. Although grantee organizations have made
strides in facilitating care coordination and establishing relationships with recovery supports, many
noted difficulties in establishing the infrastructure necessary to assist patients with the recovery
supports. Future efforts could include building models of care with embedded patient navigators in the
system who can guide individuals through the process of treatment initiation and ongoing engagement,
while at the same time providing assistance with transportation and the hierarchy of recovery supports
needed by a person living in recovery (peer supports, employment opportunities, safe and stable
housing, access to transportation, etc.).
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Peer Support for MAT Providers: Providers agree that current and future MAT prescribers could
benefit from professional mentoring, particularly providers that have newly completed the federal Xwaiver training required to deliver MAT. Most providers agree that a more formal MAT provider-toprovider network or clearinghouse would be beneficial for further training, consultation, and
information sharing.
Overdose Prevention: Given the high rates of overdoses in the state, there appears to be a need for
grantee organizations to leverage their current clinical-community linkages and cross-sector
collaboration to expand access to Overdose Prevention Education and Naloxone Distribution (OPEND)
programs. Of particular importance is developing and implementing screening protocols that identify
patients at high risk for overdoseiii and in need of overdose prevention education.
Systems to Monitor Patient Panels: Collecting valuable data on patient induction, stabilization and
maintenance remains a struggle for many grantee organizations whose electronic medical records do
not allow for easy tracking or extraction of this data for monitoring MAT patient panels. Finding
strategies to help grantee organizations implement systems for ongoing monitoring of OUD patients
will be critical to expanding practice and provider capacity for delivery of MAT.

Summary
Maine is among the states hardest hit by a national trend in non-medical uses of opioid prescription
drugs, increasing usage of heroin, and opioid-related morbidity and mortality. Addressing the opioid
epidemic in Maine is particularly challenging given the rural nature of the state. Despite ongoing state
and local efforts to improve access to treatment services for individuals with OUD, promote awareness
of the opioid epidemic and foster safe prescribing of opioid prescription drugs, rates of opioid related
overdoses and deaths continue to rise. MeHAF’s Addiction Care Program is addressing crucial access
gaps in treatment infrastructure, provider training/education, and organizational capacity to deliver
MAT in primary care settings. During the first year of the program, grantee organizations significantly
expanded their capacity to deliver MAT in primary care settings as evidenced by the number of new
prescribers and the increase in the number of patients served. As grantee organizations move into the
second year of the program, they will continue to pilot innovative strategies that address barriers to
expanding access to MAT in Maine communities.

iii

Some examples of those at higher risk for opioid overdose include: 1) persons recently entered into detoxification, 2)
persons recently released from incarceration, and/or 3) persons with a diagnosis of depression. For more information,
see: https://www.who.int/substance_abuse/information-sheet/en/
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I.

Introduction

Background

The high rate of opioid misuse and subsequent addiction is a national and local public health crisis with
significant impacts on morbidity and mortality, health care expenditures, crime, and health outcomes.
This epidemic has stemmed from high prescribing rates in the late 1990s5 and misinformation about the
addictive nature of these medications — which eventually led to diversion, high rates of misuse, and
opioid use disorder. In 2016 alone, 11.5 million people misused prescription opioids, 2.1 million people
had an opioid use disorder, and an average 116 Americans died after overdosing on opioids each day.6
Maine has been particularly hard hit by the opioid epidemic; overdose deaths have more than doubled
since 2014. In 2016, Maine had the 8th highest rate of opioid-related overdose deaths in the nation (a
statistically significant increase from 2015) and the 27th highest rate of opioid prescribing.7,8 Despite
successful statewide efforts to reduce opioid prescribing (between 2016 -2017 rates of opioid
prescriptions in Maine declined by nearly 25%), as well as efforts to increase access to treatment in the
state, rates of opioid related overdoses and deaths continue to rise.9 In 2017, there were 418 overdoses
in Maine involving pharmaceutical or non-pharmaceutical opioids, which is nearly double the rate from
2014 and accounts for 85% of all drug related deaths in the state. 10 Between 2016 and 2017, there was
an 11% increase in the total number of drug-related deaths and a 27% increase in overdoses due to nonpharmaceutical fentanyl/fentanyl analogs.11 Access to treatment is limited, particularly in rural areas, with
an estimated 25,000 to 30,000 individuals seeking treatment annually who are unable to access care
because of Maine’s limited treatment resources and infrastructure.12
Opioid use is a complex problem that needs to be addressed using a multifaceted community-based
public health approach. However, the development of appropriate interventions is complicated by the
multiple interrelated pathways to opioid addiction and the relationship between prescription opioid and
heroin use. Current research indicates prescription opioid use is a risk factor for heroin use and a subset
of people who misuse prescription opioids may progress to heroin use.13 Over the past two decades,
substantial headway has been made in understanding the root causes of substance use disorders
(SUDs); brain imaging and genetic studies suggest that addiction is a complex disease that impairs
brain functioning and is characterized by changes in the brain that persist long after drug
discontinuation.14 Moreover, because there is now substantial evidence that long-term treatments can
be effective in managing—but not curing— Substance Use Disorders (SUDs), it is reasonable to classify
these conditions as chronic illnesses.15,16 The shift from categorizing OUD as acute disorders to
recognizing them as chronic conditions means that effective treatment models should not focus solely
on acute management of withdrawal symptoms but also include long-term strategies for reducing
reoccurrence and improving patients’ treatment outcomes and quality of life. In addition, histories of
trauma are considerably more common among individuals with SUDs. More specifically, it is estimated
that individuals with a diagnosis of Post-Traumatic Stress Disorder (PTSD) engage in treatment for SUDs
at a rate five times higher than the general population and some studies have found rates of cooccurring trauma among individuals with SUDs as high as 90%.17,18 Individuals who present with histories
of trauma and OUD tend to present with a more complicated clinical picture, experience more severe
symptoms, have higher rates of additional psychiatric disorders, and poorer overall physical
health.19,20,21,22 In addition, histories of Adverse Childhood Events (ACEs) and trauma are considerably
more common among individuals with SUDs. Considering the high association between trauma and
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SUDs, comprehensive intervention strategies that incorporate trauma-informed strategies are critical to
engaging and supporting long-term recovery among individuals with OUD.

Overview of Addiction Care Program
In the face of increasing rates of overdose deaths,
escalating health care costs, and the tremendous social
costs of opioid use disorder, stakeholders from across the
state, including health care, public health, law enforcement,
government entities, and communities, have been working
to address the opioid epidemic. Within primary care, one
evidence-based strategy to address opioid use disorder
(OUD) is Medication-Assisted Treatment (MAT). MAT is the
combination of behavioral therapy with medication. For
OUD the medication is buprenorphine (common brand
names Suboxone or Subutex).23 The approach involves
long-term use of medications and is akin to insulin use
among people with diabetes. Evidence has demonstrated
that MAT is more effective at treatment retention and
reduction of heroin and prescription opiate misuse than
using time-limited medication (i.e., opioid detoxification or
tapering) or psychosocial interventions alone; the latter
approach is associated with higher rates of recurrence.24, 25
Primary care providers are uniquely situated to deliver MAT as they are at the front line of the health
care system and provide chronic disease management; 50% of opioids dispensed come from primary
care settings.26 Although the evidence supports the effectiveness of MAT for addressing OUD,
implementation in busy primary care practices remains challenging. National implementation efforts to
expand MAT have faced patient, provider, and practice-level barriers as practices undertake their
activities to either implement or expand MAT. These barriers may vary slightly by primary care practice,
but for the most part include: inadequate organizational support; limited physician knowledge and
training; poor access to supportive behavioral health services; as well as regulatory and bureaucratic
obstacles.27 ,28,29,30
Understanding the existence of these barriers, the Maine Health Access Foundation (MeHAF) is
providing funds to expand access to medication-assisted treatment (MAT) for people with OUD through
their Addiction Care Program. The foundation is currently leading a two year initiative designed to
expand access to MAT in primary care settings for medically underserved individuals with OUD. The
Addiction Care Program builds upon MeHAF’s prior work with Maine Quality Counts (QC) and the Maine
Medical Education Trust (MMET) to assess the needs and capacities of providers and practices around
the state with regard to offering MAT in primary care settings. As part of the Addiction Care Program,
MeHAF has contracted with QC to provide training, education, and technical assistance to support
grantee organizations, both individually and as a cohort. In addition, QC has sub-contracted with Eric
Haram, LADC of Haram Consulting, Maine Behavioral Healthcare, for the services of Mary Jean Mork,
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LCSW, and Maine Medical Association, principally Gordon Smith, Esq., to provide specialized assistance
in the areas of integrated treatment models for OUD, billing/coding, and public policy, respectively. The
technical assistance services are designed to support grantee organizations in making the practice
transformations necessary to effectively implement, support, and maintain MAT services in primary care
settings.
Started in April of 2017, this two-year program has provided a total of approximately $800,000 to four
planning and six implementation grantee organizations across the state of Maine. The Addiction Care
Program planning and implementation grantee organizations are working to expand access to MAT in
primary care by building capacity at the practice and provider levels. As part of their efforts to increase
the availability of MAT, grantee organizations are engaging a broad-based network of partners in their
programs to ensure the necessary referral relationships and wrap-around services to enhance access to
treatment and promote sustained, long-term recovery for people in treatment for OUD.
The four planning grantee organizations are building their practice and provider capacity to begin
delivering MAT services on a pilot basis. Table 1 provides a brief overview of the planning grantee
organizations with information from their initial grant applications; current work has evolved and been
refined.

Table 1. Planning Grantee Organizations
Lead Organization

LincolnHealth

Project Description

Geographic Area
of Focus

LINKING A COMMUNITY: BRINGING PEOPLE TOGETHER FOR COMPREHENSIVE MAT
Assess provider capacity for MAT expansion and build on existing relationships
Lincoln County
with medical and social service providers, specialty addiction care services, and
representatives from the recovery and treatment communities in order to
improve access to patient-centered treatment through a county-wide MAT
program.

SOMERSET EXPANSION FOR ADDICTION CARE COLLABORATIVE
Convene provider and community stakeholders to develop an implementation Somerset County
plan that will meet the need for a more integrated system of care among
primary care, specialty care, consumers, and critical stakeholders, with
Kennebec Behavioral Health as the lead.
CommUNITY: A COLLABORATION TO EXPAND PATIENT-CENTERED ADDICTION CARE
Tri-County Mental Organize a coalition of local organizations through a Steering Committee and
Androscoggin
Health Services
Subcommittees to design the structure of a “virtual organization” of multiCounty
disciplinary providers to provide MAT services for uninsured and underinsured
populations.
YORK HOSPITAL INTEGRATED MEDICATION ASSISTED TREATMENT (IMAT) INITIATIVE
York Hospital
Establish a collaborative and multidisciplinary network of internal and external
York County
partners to develop a patient-centered system of addiction care through a huband-spoke model to provide capacity for triage, diagnosis and referral to MAT
services.
Kennebec
Behavioral Health
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The six implementation grantee organizations are working on expanding their existing capacity to
deliver MAT in primary care settings, enhance their capacity to provide low barrier access to MAT, and
increase the number of patients receiving MAT services through their programs. Table 2 shares a brief
overview of the implementation grantee organizations with information from their initial grant
applications; current work has evolved and been refined.

Table 2. Implementation Grantee Organizations
Lead Organization

Amistad

Project Description

Geographic Area
of Focus

DEVELOPING AND IMPLEMENTING A GENDER-SPECIFIC OPIOID HEALTH HOME FOR WOMEN
Develop a gender-specific Opioid Health Home for women, with a focus on Cumberland and
effective care coordination and safe housing options, and expand provider
York Counties
capacity for MAT in primary care medical homes through a hub-and-spoke
model.
HEALTH ACCESS NETWORK MAT EXPANSION

Health Access
Network

Healthy Acadia

Healthy
Community
Coalition

Increase care coordination and management support for MAT providers, and
provide training and supervision for Advanced Practice Clinicians regarding
MAT, as well as training in behavioral health, drug, and alcohol treatment.
DOWNEAST OPIOID TREATMENT HUB AND SPOKES PROJECT
Expand the community-based Downeast Opioid Treatment Hub and Spokes
Project, Peer Recovery Coach Services, and alternative pain management
strategies.
RURAL ADDICTION CARE EXPANSION (RACE) TO RECOVERY
Lead a community-wide effort to increase provider capacity and access to MAT,
with a focus on providing patient-centered addiction care to pregnant women,
new mothers, and infants.

Penobscot
County

Hancock and
Washington
Counties
Franklin and
Oxford Counties

EXPANDING ACCESS TO MAT IN THE CENTRAL MAINE REGION’S PRIMARY CARE PRACTICES
MaineGeneral

Penobscot
Community Health
Care

Train and support currently prescribing physicians and newly prescribing
physicians, physician assistants, and nurse practitioners to provide MAT by
navigating system improvements to practice workflows and cross-organization
tracking.
A REGIONAL, RAPID-ACCESS APPROACH TO MAT
Integrate a regional, rapid-access clinic in primary care that offers Suboxone
(buprenorphine) induction, primary care, individual and group counseling
sessions, and care management.

Kennebec,
Somerset, and
Sagadahoc
Counties
Penobscot,
Somerset, and
Waldo Counties

II. Evaluation Methodology
Overview
The Muskie School of Public Service at the University of Southern Maine was contracted by MeHAF to
conduct an independent evaluation of the implementation and effectiveness of the Addiction Care
Program. This program evaluation is designed to inform current and future planning activities; guide
the implementation and refinement of the intervention strategies; provide ongoing feedback to grantee
organizations on improvements to access and delivery of MAT in their region; and offer a summative
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assessment of the implementation experience and success of the intervention strategies. The primary
goals of the Addiction Care Program year one evaluation activities were to:




examine the structural factors (external context) and organizational-level factors (internal
context) that influence the planning or implementation of MAT in primary care settings;
assess the barriers and facilitators to expanding access to MAT for medically underserved
populations; and
document successes and lessons learned from initial planning and implementation activities.

The evaluation team utilized a mixed-methods design, including the collection of both quantitative and
qualitative data, to document the implementation environment; examine factors impacting availability
and access to MAT; and evaluate grantee strategies and whether and/or how these approaches reduce
barriers to access to treatment and recovery supports for individuals with OUD.

Data Collection
Administrative and Clinical Data: During the first six months of the grant, the evaluation team worked
with grantee organizations to develop cross-site and site-specific metrics to track strategies, goals and
outcomes. Grantee strategies and goals were guided by Site Self Assessments which were completed
by all grantee organizations. Data dashboards were developed using Excel spreadsheets to assist
grantee organizations’ tracking of cross-site and site-specific metrics and provide rapid cycle feedback
on program strategies through continuous quality improvement (CQI) metrics. These dashboards were
developed collaboratively with each grantee organization, based on their goals and data collection
needs, in consultation with Muskie and Eric Haram. In health care systems, data dashboards are
frequently used to manage and track health care information, CQI metrics and other essential measures
to monitor programmatic performance and patient outcomes. During year one of the Addiction Care
Program, planning grantee organizations collected administrative data on: education and training,
stakeholder engagement, and capacity building (e.g. new policies, workflows, waivered providers).
Implementation grantee organizations tracked clinical CQI metrics related to screening and assessment,
treatment initiation, stabilization, and maintenance including: number of patients screened for OUD,
total patients diagnosed with OUD, total patients induced on buprenorphine, number of behavioral
health referrals, number of urine drug screens and number of patients with universal agreements.
Aggregate administrative and clinical data from the dashboards provides valuable feedback about
grantee milestones and challenges faced during the first year of the initiative.
Surveys: Gathering data on organizational climate (including provider attitudes), practices, and patterns
of care is crucial to enhancing efficiency in health care delivery while continuing to improve patient
outcomes. Baseline surveys were used to gather data on organizational climate, readiness for change
and provider attitudes and behaviors. A total of 302 surveys were distributed to executives, Change
Team members and providers between September and October of 2017 using Snap Survey Software, a
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web-based survey tool. A total of 150 surveys
Targeted Survey Respondents
were completed for a response rate of 50%,
which is consistent with electronic survey
Executive: Individuals who are part of health system or
response rates among health care providers.31
organizational executive leadership.
Thirteen percent of survey respondents were
Change Team: Individuals who are involved in the day to
executives, 35% were Change Team members
day collaborative and operational aspects of project
and 52% were providers. The majority of
implementation.
survey respondents were female (65%) and
Providers: Prescribers and anyone with direct interactions
between the ages of 45 and 64 (56%). The
with participants/patients. This staff includes but is not
bulk of provider respondents were from
limited to: MD/DOs, PAs, RNs, LPNs, CMA/MAs, managers,
planning sites (78%), most likely due to the
LCSWs, and other behavioral health staff.
fact that sites defined potential participants
for recruitment and planning sites included
nearly three times as many providers in their
recruitment pool. At the time of the survey, only 16% of provider respondents had completed the Drug
Treatment Act of 2000iv required training and certification to obtain the required X-waiver to prescribe
buprenorphine.
Interviews: A total of 36 providers from participating sites were interviewed during year one of the
program. Staff who agreed to participate were asked about the challenges associated with
implementing MAT; the health system, practice or provider-level factors that facilitated the
implementation process; organizational factors that impact the planning and implementation process;
and individual, provider-level issues that influence the adoption and delivery of MAT. All providers
(including prescribers and anyone with direct interactions with patients; parallel to provider survey
respondents) engaging in MAT activities were eligible to participate in the semi-structured group
interviews.
Focus Groups: In an effort to understand barriers and facilitators to accessing care for OUD, as well as
current service gaps and unmet needs, eight focus groups were conducted throughout the state with
persons in recovery from the grantee organizations (n=37). Persons in recovery, including those
currently in treatment, planning on engaging in treatment, and/or engaged in the planning and
collaboration of the Addiction Care Program efforts were interviewed. Domains of interest included:
experiences initiating and engaging in treatment; barriers and facilitators to accessing care for OUD;
patient experiences receiving MAT; the impact of MAT on patient commitment to treatment and
recovery; current unmet treatment and recovery needs; and patient recommendations for enhanced
patient-centered care.

iv

The Drug Addiction Treatment Act of 2000 (DATA 2000) expands the clinical context of medication-assisted opioid dependency
treatment. Qualified physicians are permitted to dispense or prescribe specifically approved Schedule III, IV, and V narcotic
medications (medications that have a lower risk for abuse, like buprenorphine) in settings other than an opioid treatment
program (OTP). OTPs provide medication-assisted treatment (MAT) for people diagnosed with an opioid use disorder.

May 2018

12

INTERIM EVALUATION REPORT

Data Analysis
Muskie utilized both quantitative and qualitative data analysis techniques to analyze and triangulate
data collected from organizations, providers, and patients. In order to maintain the confidentiality of
respondents, all data presented in this report has been de-identified and presented in the aggregate.
Quantitative administrative, clinical, and survey data were analyzed using appropriate descriptive
statistics such as means and frequencies; analysis was conducted in Microsoft Excel and SAS 9.4.
Qualitative data (e.g., semi-structured interviews, focus groups, key documents) were systematically
coded to explore how the implementation of MAT in primary care practices unfolds using the qualitative
software program NVivo.32 Qualitative data analysis was done iteratively to build a coding scheme for
all textual data using the grounded theory technique, in which codes are drawn from the text and coding
involves frequent comparative analysis of the data. We compiled a code book of emerging themes and
constructs with attention to those elements suggested to be important for successful implementation
of MAT in primary care settings. Qualitative data was compared with quantitative data to further
explicate and validate findings and to identify areas needing exploration.
The evaluation team and MeHAF recognize the importance of language in perpetuating the stigma
associated with OUD. Therefore, throughout this report, data is presented using recommended
terminology from the Substance Abuse and Mental Health Services Administration guide to language.33
For a more detailed description of key terminology used throughout this report please refer to Appendix
A, Glossary of Key Terms.
Data is presented using traditional graphs and tables as well as infographics and exemplar quotes taken
from interviews and focus groups. It is important to note that some of the quotes from patients include
terminology that reinforces stereotypes about individuals with OUD. These verbatim quotes represent
the views of individuals with OUD and it is important for us to allow individuals with substance use
disorders the autonomy to define how they identify themselves.34 Moreover, the inclusion of patient
perspectives is essential to understanding how to effectively address stigma as well as other key barriers
and facilitators to expanding access to patient-centered care for OUD.

III. Evaluation Results
Implementation Context
External Implementation Environment: Improving the quality of treatment for OUD through the
implementation of evidence-based treatment practices (EBPs) has increasingly been the focus of federal
and state agencies. However, research indicates that initiatives aimed at promoting the widespread
implementation of MAT programs are often undercut by limited infrastructure, public policies,
insufficient reimbursement, and limited financial resources.35 There is a growing awareness and a
readiness in Maine to develop strategies to overcome these barriers and enhance the state’s ability to
effectively address opioid misuse and OUD. The work being carried out by the Addiction Care Program
grantee organizations aligns and expands upon existing state and local efforts to increase capacity in
the state to prevent and treat OUD. For example, the Maine Opiate Collaborative (MOC), which was led

May 2018

13

INTERIM EVALUATION REPORT

by the U.S. Attorney’s office, was established in September 2015 to facilitate the creation of a broad,
multi-dimensional approach to addressing OUD in the state including education, prevention, treatment,
recovery, and law enforcement. The Collaborative created three multi-stakeholder task forces which
made recommendations for clinical, policy, and funding changes needed to address the opioid crisis
across the state (released in May 2016). A legislative taskforce was formed in the spring of 2017 and
charged with examining the MOC recommendations, as well as current laws, and initiatives undertaken
by other states, to develop a set of recommendations to address Maine’s opioid crisis. (Note: the Opioid
Taskforce released its final report in December of 2017 and is no longer meeting.) Many of these
recommendations are being addressed by Addiction Care Program grantee organizations. As part of its
policy strategy to lessen the opioid crisis, the Maine Legislature passed a strict new opioid prescribing
law that went into effect in July 2016 and is the current environment under which providers are
prescribing opioids. The 2016 law made five major changes to opioid prescribing. It:






mandates use of the State’s Prescription Monitoring Program (PMP) and expands its users;
enacts strict limits on opioid prescribing for acute and chronic pain (ALL opioids, not just
Schedule II);
mandates education for opioid prescribers;
mandates electronic prescribing of opioids;
provides for a “Partial Fill” at a pharmacy, at the direction of the patient.

Additionally, the prescriber licensing board’s Chapter 21 rules require additional actions in connection
with opioid prescribing, such as universal precautions for opioid prescribing; opioid continuing
education requirements for all licensees of the Board of Licensure in Medicine (the MD Board); and
mandated urine drug screens for patients. Implementing the new opioid prescribing law has been a
considerable effort and both QC and MMA continue to offer technical assistance and provider education
to bring providers into compliance with the new regulations. The challenges health systems and
providers have faced translating the new policy into practice highlight the need for supports like the
Addiction Care Program, that provide the resources necessary to facilitate both practice transformation
and build organizational and provider capacity to effectively address OUD in primary care settings.
In addition to other state-level policy changes, the Maine Department of Health & Human Services,
Office of Substance Abuse and Mental Health Services established an Opioid Health Homes program
(OHH) that provides funding to providers who deliver MAT to patients with OUD to cover costs of
intensive, intermediate and long-term treatment, including, but not limited to, the cost of medication,
screening, behavioral health treatment and office visits for 1,000 uninsured patients. However,
programmatic requirements have made it difficult for the majority of practices and providers in the state
to participate in the OHH program; several of the grantee organizations are leveraging the MeHAF funds
to help implement the infrastructure necessary to qualify for the program. In addition to the efforts led
by the State of Maine, QC and MMA have led a collaborative effort, Caring for ME, since 2016 that aims
to bring together a wide set of partners to promote shared messages, educational resources, and
practical tools to enhance provider capacity to deliver MAT and provide ongoing training and support
to providers delivering MAT.
Although the state has begun to implement the OHH program to provide MAT and care coordination
for low-income individuals living in Maine, the state has been unable to expand access to treatment
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through Medicaid expansion. Medicaid programs have historically filled critical gaps in responding to
public health crises and research indicates that of nonelderly adults with OUD, those with Medicaid are
twice as likely as those with private insurance or no insurance to receive treatment.36 Medicaid facilitates
access to treatment by covering numerous inpatient and outpatient treatment services, as well as the
medications prescribed as part of MAT. Maine voters approved Medicaid expansion through a
referendum in November of 2018. The decision to expand Medicaid coverage in Maine has the potential
to transform substance use disorder treatment in the state however, implementation of expansion has
been delayed by disagreements between the executive and legislative bodies on how to fund the
program. The costs associated with MAT are major barriers to accessing care for OUD in Maine. Medicaid
expansion would make at least 70,000 additional Maine residents eligible for Medicaid and, as evidenced
by expansion states who saw treatment for substance use disorders increase under expansion, could
play a vital role in increasing access to treatment for OUD and decrease opioid related morbidity and
mortality.37
While the Addiction Care Program is being implemented at a time when there is considerable interest
in developing strategies to expand the state’s treatment infrastructure, there are still substantial barriers
to expanding access to MAT in Maine. Despite support at both the governmental and health systems
levels, there remain substantial policy level barriers to increasing access to MAT. Legislative efforts to
address the need for expanding the state’s prevention and treatment infrastructure have not yet
provided the resources necessary to fully implement the recommendations put forth by the Taskforce.
As a result, health systems are seeking alternative solutions to address the needs of their patient
populations. There are currently several efforts being led by health systems, community-based
collaborations, and social service agencies across the state to expand access to treatment and recovery
supports for individuals with OUD.
Internal Implementation Environment: Although the broader statewide implementation climate is
critical to supporting efforts to expand the use of MAT to address OUD, organizational culture and
readiness are increasingly recognized as factors that play a key role in determining the success of quality
improvement efforts aimed at addressing substance use disorders. Research indicates that under the
right circumstances, primary care practices that are ready to implement evidence-based care can do so
if they are provided with effective facilitation and training.38 Health care organizations that emphasize
teamwork, coordination, and communication among staff have been associated with higher rates of
successful implementation of quality improvement activities including operationalizing new policies,
programs, and practices. Moreover, research indicates that efforts to improve the delivery of evidencebased care that focus only on provider knowledge and decision support have been largely unsuccessful.
Interventions that target providers and promote practice transformation, are critical to improving the
quality of care.39
Organizational Readiness: Baseline survey and interview data from Addiction Care Program grantee
organizations indicates that participating sites are motivated and ready to implement MAT programs.
The primary reason individual grantee organizations pursued participation in the Addiction Care
Program was a clear need to address OUD at the community level.
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The
2015
Maine
Shared
Survey Participants and Response Rates
Community
Health
Needs
Survey
Participants
Response
Assessment, a coordinated effort
Type
Rate
led by several of the state’s largest
Executive
Individuals who are on health system or
N=19/36 (53%)
health systems and the Maine
organizational executive leadership.
Center for Disease Control and Change
Individuals who are involved in the day to
day collaborative and operational aspects
N=39/64 (61%)
Prevention
(Maine
CDC), Team
of
project
implementation.
identified drug and alcohol use
Individuals include prescribers and anyone
disorders as the top-ranked Provider
with direct interactions with
health issue in the state. Executive
participants/patients. This staff includes
N=92/193 (48%)
leadership
at
the
grantee
but is not limited to: MD/DOs, PAs, LPNs,
RNs, CMA/MAs, LCSWs, managers, and
organizations reported actively
behavioral health staff.
seeking out opportunities to
Overall Response Rate: (150/302) = 50%
address this clearly identified
40
issue within their service areas.
Moreover, the majority of executives, Change Team members and providers (86%) associated with
grantee organizations strongly agreed/agreed that expanding access to MAT through the Addiction
Care Program would lead to improved patient outcomes for individuals with OUD. Implementation
grantee organizations (98% implementation vs. 81% planning) and Change Team members (97%
Change Team vs. 79% non-Change Team) were significantly more likely to feel that expanding access
to MAT in primary care settings is fundamental to improving patient outcomes (p < 0.01). Many
respondents reported that expanding access to MAT is important because it is an evidence-based
treatment that is proven to be effective in saving lives and helping many patients recover from OUD. In
addition, three out of four survey respondents indicated that they strongly agreed/agreed that
expanding access to MAT in primary care settings is supported by evidence and takes into consideration
the needs and treatment preferences of patients. These findings are supported by the data we collected
through conversations with patients. The majority of focus group participants indicated that they had
engaged in a variety of different treatment programs, but officebased outpatient MAT was clearly articulated as their preferred
treatment mode. This was largely due to the fact that outpatient
“MAT saves lives and works to
MAT programs, particularly for those in long-term recovery, were
bring people into recovery.”
viewed as the most expedited low-barrier way to access
-MAT provider
buprenorphine with care management, linkage to wrap-around
treatment and primary care, as needed.
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Organizational Culture: Organizational culture and climate plays a key role in ensuring the successful
implementation of clinical interventions.41 Survey responses indicate that the organizational culture at
grantee
organizations
facilitates
the
use
of
innovative strategies to
improve patient experience
and promotes population
health. Survey respondents
indicated that staff members
at their organization have a
sense
of
personal
responsibility for improving
patient care and regularly
work to improve the efficacy
of the care they provide
(Figure 1). The majority
(82%)
of
respondents
strongly agreed/agreed that executive management in their organization believes that current practice
patterns can be improved. Yet, providers were significantly less likely than non-providers (i.e. Executive
and Change Team members who were not providers) to strongly agree/agree that clinical innovation
and creativity designed to improve patient care is rewarded; 42% versus 75% respectively. In addition,
providers were significantly less likely than non-providers to feel that senior and/or clinical leadership
at their organization provide clearly defined responsibilities, promote a team-based approach to
addressing issues related to clinical care, and facilitate communication between clinical services
departments; all important components to effectively implementing integrated models of care for
complex conditions such as OUD (Table 3).
Table 3. Strongly Agree/ Agree that Senior Leadership / Clinical Management in My Organization…
Provider (n=54)
Non-Provider (n=89)
Clearly define areas of responsibility and authority
53% (n=47)
76% (n=41)*
for clinical managers and staff
Promote team building to solve clinical care
55% (n=49)
80% (n=43)*
problems
Promote communication among clinical services
60% (n=53)
80% (n=43)*
and units
* Statistically significant difference between Providers and Non-Providers (p<.01)
Organizational leadership plays a pivotal role in facilitating the implementation and sustainability of
change within clinical practices. In order to effectively integrate MAT into primary care settings, senior
administrative and clinical leadership must perceive the value of investing in proactive, chronic care
treatment models as well as provide the resources necessary to support integrated care, including
investing in information systems and outcomes measurement. Although providers express mixed views
about organizational leadership regarding MAT implementation or expansion, members of the Change
Team who are primarily responsible for implementing the project strategies at each site, did feel that
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executive and/or clinical leadership within their organization agreed upon the goals of their Addiction
Care Program project and that leadership has prioritized the success of the program (Figure 2). Yet, it is
important to note that Change Team members strongly disagreed/disagreed or reported neutral
responses when asked if leadership agrees upon the resources necessary to achieve programmatic
goals. This indicates that organizational leadership may not have a full understanding of the resources
necessary to effectively implement their programmatic strategies (Figure 2). These results signify that
there is a need for more formal feedback structures required between Change Teams and Executive
Leadership.

Research indicates that even within organizations that are highly motivated to implement MAT to
address OUD, insufficient organizational investment of resources as well as external funding policies
that fail to sufficiently reimburse for provider time and other MAT-related expenses can create major
barriers to implementation.42 When asked about the challenges organizations face when trying to
implement or expand MAT services, the broader group of respondents reiterated the concerns
expressed by Change Team members about the resources devoted to the initiative. In addition to
concerns about lack of funding and budgetary restraints, respondents also indicated that there is often
a lack of support in terms of staffing as well as appropriate training and education to help facilitate the
implementation of new policies and protocols (Figure 3).
In order to successfully
implement change within
health
care
settings,
organizations need to have a
clear vision, well-defined
plans and expectations of
providers as well as staff
supports for implementation.
As part of the Addiction Care
Program, over the past year,
grantee organizations have
engaged in comprehensive
planning and implementation
processes which have allowed them to effectively address some of the organizational culture and
climate issues described above.
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Grantee organizations report using multi-pronged
strategies that are focused on creating
organizational cultures that help facilitate the implementation process (e.g. updating workflows,
policies, procedures) while simultaneously utilizing targeted training and education strategies to
enhance providers’ abilities and willingness to deliver MAT. As a result, grantee organizations have been
able to overcome organizational barriers and create implementation environments that are much better
equipped to offer providers the supports they need to integrate MAT into their clinical practice.
Provider Motivation and Readiness: Despite overall high motivation to help individuals with OUD, survey
respondents from implementation projects (vs. those on planning projects) or on a Change Team (vs.
those not on a change team) were significantly more likely to want to work with individuals with OUD.
Twenty percent of respondents were ambivalent towards working with individuals with OUD and 18%
did not want to work with these individuals. Concerns over lack of provider willingness was a noted
challenge to MAT expansion, including hesitation to participate and providers’ perceptions of “too many
hoops/barriers to patients entering care” for them to consider becoming involved. These findings mirror
national research that indicates a reluctance to use MAT among providers; frequently cited factors
include: negative attitudes about MAT; insufficient or inaccurate knowledge about MAT in the general
medical community; inadequate reimbursement for MAT services; and a lack of resources needed to
effectively provide and support MAT programs.43 It is important to note that project managers of
grantee organizations determined to whom the surveys were deployed, and therefore the surveys may
have reached a wider breadth and more diverse pool of providers compared to those interviewed.
Providers reached through surveys may not have been aware of their respective site’s MAT project or
may have been less supportive of the work of the project.

Barriers to Expanding Access to Treatment for OUD
Organizational-Level Barriers:
Resources: The most commonly identified challenge to expanding access to MAT among executives,
Change Team members, and providers was a lack of funding and the budgetary constraints faced by
their organizations. Providers indicated that reimbursement for services was the number one barrier to
expanding access to MAT. In addition, providers indicated that there are a number of administrative,
infrastructure, and compliance issues that make implementing and
delivering MAT difficult in primary care settings. Many participants
“If we could get the cost or
expressed concerns about administrative and regulatory burdens;
reimbursement barriers out of the
increases in workload; expanded responsibilities related to
way, the things we’re talking about
coordinating the care of complex patients; and the challenges
associated with navigating reimbursement policies. For example, on the ground about changing
many providers indicated that they and their organizations lack hearts and minds—we can do that if
understanding about obtaining reimbursement for office-based we just keep working at it.”
-MAT Provider
medication management, which presents additional challenges for
expanding access to MAT in primary care practices.
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Provider and Program Shortages: Patients frequently cited the lack of available MAT providers in their
community as a barrier to access care. Workforce shortages and staff turnover continue to constrain the
ability of organizations to expand access to
MAT. In our discussions with providers they
“This epidemic … probably wouldn’t be half as bad
continually mentioned not having enough
if everybody had access to help when they wanted
providers and counselors to effectively address
the demand for services in their communities. In
it. I wanted help a long time before I got it.”
-Person in recovery
addition, providers are faced with limited staff
to help with scheduling and managing care
coordination for MAT patients. A lack of staff to
oversee these activities has forced prescribers to limit the size of their MAT patient panels. As one
prescribing provider noted, “the irony of that stigma (perceived work burden) is if we could spread
this out over more people, it wouldn’t be so onerous.” In addition, particularly in rural areas, patients
are faced with limited access to detoxification and MAT treatment programs because of the states
limited treatment infrastructure.
Provider-Level Barriers:
Provider Training: Research indicates that primary
care providers recognize the importance of
“I think it is a little daunting that you have to go
addressing OUD and increasingly view it as part of
through an extra step to get this X waiver, and
their clinical responsibilities.44 However, despite
there’s a lot of things you have to keep track of in
ambitious efforts nationwide to implement
comprehensive screening and MAT for OUD in order to do it properly. I’m sure the majority of us
primary care, the number of primary care providers prescribing are going to be audited at some point,
so I think there’s some fear there. It’s not just
delivering MAT remains low, particularly in rural
prescribing someone’s blood pressure medicine.”
states such as Maine. Providers expressed a wide
-MAT Provider
range of comfort levels related to working with
individuals with opioid use disorder and the
delivery of MAT; many lack confidence in their
ability to manage patients with opioid use disorder. Lack of proper training, expertise, and tools for
providers and staff were regularly mentioned as barriers to expanding access to MAT. The workforce
challenges associated with implementing MAT into primary care settings are significant and providers
expressed apprehensions about the time-constraints associated with working with patients with
complex medical needs. Based on the feedback we received from providers, in order to effectively
expand access to MAT, it appears there is a need for trainings for a variety of providers (prescribers,
nurses, social workers, therapists, counselors, peer recovery coaches, etc.) as well as a sustained
investment in developing the appropriate infrastructure and supports for staff all at levels. In order to
address these issues, grantee organizations made significant investments in training and education
throughout the first year of the project.
Stigma: Providers reported that stigma among medical providers and staff often underlies or
compounds the challenges associated with many of the barriers to MAT expansion that were noted
above. In general, many providers are uncomfortable with treating individuals with OUD due to the
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nature of the disease. As one doctor noted, “Negative factors of why other potential prescribers
don't do it would be they're uncomfortable with the medication, with the patients, with the
disease process.” In addition, many providers continue to be resistant to addressing OUD in primary
care. “That’s the biggest hurdle. If we could convince providers that this is part of treating your
patient just like anything else, then you might get more buy-in.” Concern over liability if patients
experience a recurrence while on MAT prevents many therapists and medical and behavioral health
providers from delivering MAT. As such, misconceptions about processes and workloads held by
providers produce a fear of treating OUD, which contributes to the lack of providers willing to prescribe
medications for OUD treatment. Providers reported that if there were more resources and infrastructure
in place to support MAT providers, more attention could be placed on addressing stigma.

Barriers to Initiating and Engaging in Treatment for OUD
Barriers to initiating and engaging in treatment for OUD such as health care workforce shortages,
transportation limitations, and stigma have been well documented in the literature.45 Furthermore,
individuals in rural communities are often disproportionately impacted by these barriers and individuals
with OUD living in rural areas are often faced with additional challenges to accessing treatment and
recovery services. In our discussions with providers and patients, seven primary themes emerged as
obstacles to accessing treatment for OUD
including: lack of insurance, inflexible
“I think there’s still a lot of stigma across medical
treatment program policies (i.e., getting
“kicked out” of treatment for missing a providers, and that is a service barrier. There’s also
meeting), cost of Suboxone, transportation, really unrealistic views that this is going to add a
ton of time to people’s practices.”
disruptions in care, time commitment, stigma
-MAT Provider
and lack of awareness (see Patient and
Provider Perspectives: Barriers to Accessing
Treatment infographic, next page).

May 2018

21

INTERIM EVALUATION REPORT

Identifying Pathways to Treatment: Overall, patients cite a number of reasons why initiating and
engaging in treatment can be difficult even when they are ready to seek help. The majority of patients
indicated that there are often no clear paths for individuals seeking treatment for OUD (for one example
of how a person might enter MAT in a primary care setting, see Example Clinical Pathways for MAT
infographic, next page). Inadequate detoxification and treatment options, coupled with the lack of MAT
providers in the state, makes identifying and accessing treatment difficult for patients. The majority of
individuals reported using informal social networks to identify sources of treatment and gain an
understanding of how to access care. Patients reported a variety of mechanisms for identifying and
entering into treatment; while some people initiated treatment via court order or through the criminal
justice system, others reported seeking help through a health care provider or using online resources
or the phonebook to identify treatment options. These patients describe spending hours on the phone
or online trying to identify a MAT provider; when they did identify potential prescribers they were often
told the provider was no long offering MAT services, or was at full capacity.
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Moreover, both providers and patients
indicated that once an individual
identified a potential source of treatment
they often faced additional barriers to
initiating care including long wait times
to see prescribers, lack of access to
detoxification facilities, lack of insurance
and/or the financial resources to pay for
treatment and medications, and the
inability
to
meet
the
intensive
requirements,
including
time
commitments, often required as part of
OUD treatment program. (See Patient
Feedback: Barriers to Treatment Initiation
infographic, next page.)

"More knowledge is needed
about Suboxone ... my family
can't understand you can't get
high off it."
-Person in recovery

Patients overwhelmingly indicated a
need for education and outreach to
family and friends about treatment
options and the use of MAT to address
OUD so that peers and loved ones will be
more likely to assist patients with getting
access to treatment. Patients frequently
mentioned the need for in-depth,
consistent, evidence-based education to
individuals, friends and family members
regarding treatment options and the use
of MAT to address OUD. Many
individuals also mentioned the need for
outreach about available services in their

communities so family and friends can help individuals get access
to treatment when needed. Many respondents indicated that they
were unaware of treatment services in their area with one individual
noting: “For such a small town we have an amazing system,
but still people know nothing about it.”

"More knowledge is needed
about Suboxone ... my family
can't understand you can't get
high off it."
-Person in recovery

In general, patients saw education and outreach as essential tools in raising awareness about available
treatment options, while at the same time helping to reduce the stigma associated with OUD and MAT.
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Costs: Among persons interviewed, the cost of treatment services and prescription medications was by
far the most prohibitive barrier to accessing and engaging in treatment for OUD. Both patients and
providers frequently discussed the fact that the majority of patients seeking treatment for OUD in Maine
are underinsured or uninsured. In fact, Mainers who
are out of work or living below the poverty line are
“I watched people that I knew … in and out, in
at the highest risk for OUD. Even individuals with
and out (of treatment), and it is mostly because
insurance discussed the high out-of-pocket costs of
of money. There is not enough funding out
MAT, including the expense of paying for
there to get clean.”
buprenorphine. Participants frequently cited the
-Person in recovery
high costs of medication and the varying costs of
prescriptions by region and pharmacy: “I pay $60 a
week for prescriptions, and $65 for the (weekly)
treatment group, so it comes out to $500 a month for Suboxone.”
Treatment Policies: In addition to the challenges associated with the affordability of MAT, both patients
and providers reported that inflexible treatment program policies as well as external policies such as
MaineCare’s cumbersome prior authorization process, make it difficult to have continuity of care in
treatment and recovery. As with other chronic relapsing conditions, the clinical course of OUD includes
periods of exacerbation and remission, but the patient is never disease-free.46 Patients report past
recurrences, missing appointments or group therapies, and changes in insurance that often put them
back at “square one” in an intensive outpatient program. Patients clearly articulated the need for a
spectrum of treatment and recovery services that allow for multiple points of entry and accommodate
the chronic relapsing nature of OUD. This suggests the need for a broader application of team-oriented
Chronic Care Models (CCM). The implementation of
a CCM reorients care from acute, procedure“If you mess up one time or two times they don’t
oriented care to sustained patient-oriented
want to take you back. You know addicts are
practices which can facilitate a treatment options
going to relapse. It seems like they just don’t
that recognize the chronic nature of OUD. The CCM
want to keep giving you chances.”
offers a framework for achieving evidence-based
-Person in recovery
care by providing flexibility for individuals with OUD
and promoting an integrated model of care to
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address the complex needs of patients. Consistent with CCMs used to manage other chronic diseases
such as diabetes, treatment plans for OUD need to be patient-specific and created with input from the
patient, the prescriber, and other members of the health care team. This dual approach to OUD
treatment is supported by medical and behavioral health groups, including the American Society of
Addiction Medicine and the National Council for Behavioral Health, patient advocate groups, and federal
entities including the White House Office of National Drug Control Policy and the U.S. Surgeon
General.47
Transportation: Nationwide only 1.3% of waivered providers practice in rural communities, which
means individuals seeking MAT must often travel long distances to access care.48 Therefore,
transportation is a particularly salient barrier for individuals seeking treatment for OUD in Maine. Both
patients and providers mentioned that the lack of safe and affordable transportation presents major
challenges for individuals trying to access and engage in
treatment. Rural communities in Maine often lack
“Transportation is another big deal. I was
detoxification services, MAT providers, and specialty
getting my Suboxone out of Portland and
mental health and substance use treatment programs.
Geographic proximity to services, and lack of that is quite a hike when you have to
chase your pills.”
transportation or resources to obtain transportation to
–Person in recovery living 55
reach these limited services, were frequently discussed
miles from Portland
as barriers to accessing treatment. In addition, patients
discussed the fact that unreliable transportation was the
primary cause of treatment non-compliance (e.g.
missing appointments, pill counts, urine screens) which could result in termination from the program.

Stigma: Increasingly, governments and professional organizations are mobilizing resources towards
preventing and managing health-related stigma.49 However, the stigma associated with opioid use
continues to be a major barrier for providers of MAT as well as patients in treatment and recovery.
Health-related stigma is often described as a socio-cultural process in which social groups are devalued,
rejected and excluded on the basis of a socially discredited health condition.50 Stigma can manifest itself
at the individual, social and societal levels. Research indicates that stigma is a significant barrier to
accessing treatment for substance use disorders and has negative impacts on treatment completion
rates.51 Both providers and patients acknowledged that stigma remains a major barrier to accessing
treatment for OUD. Patients reported that stigma related to their OUD adversely impacted many
domains of life such as treatment engagement, employment, housing, and social relationships. In
addition, patients reported feeling stigma from family and friends, providers, pharmacists, and from
members of their communities. Several patients noted that they felt stigmatized for their use of
medication in their recovery by other individuals using the abstinence-based treatment model of
recovery. Providers also conceded that stigma around treating persons with opioid use disorder remains
a problem in the provider community: “A lot of providers don’t see it as part of primary care, which
is unfortunate - because it is.” Both providers and patients reiterated the need to address stigma
surrounding opioids and to educate the community about OUD and MAT.
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Facilitating Access to Treatment for OUD
Low barrier access to treatment, insurance coverage (private or public), provider supports, and having
treatment options were frequently cited as key factors in being able to access and initiate treatment.
Low Barrier Access to MAT: Patients and
providers overwhelmingly agreed that “You want to get into a place and it takes seven days.
programs that reduce barriers to accessing They want to admit you to a program and all of this
care, including low barrier access to
(waiting) makes people give up. It is real easy to give
detoxification services, are essential to
up you know.”
increasing access to treatment for individuals
-Person in recovery
with OUD. A large 2016 study showed that
MAT – including a specific prescribed
medication such as buprenorphine that reduces or eliminates drug cravings – cuts the death rate by
50% for people with OUD, when compared to routine substance use disorder treatment that does not
include a pharmaceutical medication.52 Therefore, for individuals with OUD, easy access to affordable
life-saving medications is critical. Access to medication supports was so important that some
participants reported resorting to using diverted medication when they are unable to gain access to
buprenorphine through a prescriber or treatment program. In addition, long wait times promote the
use of cash providers who often do not provide comprehensive MAT services. Patients see these
providers as the quickest way to get access to buprenorphine to stabilize themselves. Unfortunately,
many patients reported that the high costs associated with utilizing cash providers often led them to
divert a portion of their prescription to afford the services. These findings provide further evidence of
the importance of expanding provider capacity and low barrier access programs that can promptly
engage patients who are seeking care in evidence-based treatment programs.
Insurance Coverage: Insurance coverage (private or public) was identified as a key factor in being able
to access and initiate treatment. Even individuals with insurance face cost barriers as many insurance
companies do not pay for the costs of patients’
buprenorphine prescriptions. The majority of
individuals with OUD we talked to did not have “Insurance companies will say they approve
insurance or were underinsured, which created (MAT) in the beginning … and those people go
additional obstacles to accessing care. Although to treatment and they get out and they have a
progress has been made in increasing access to (huge) bill because their insurance only picked
medications approved for the treatment of OUD, up part of their treatment.”
significant barriers still exist with regard to benefits
-Person in recovery
and coverage of medications that can be used as
part of comprehensive treatments to address OUD.
Medicaid expansion has the potential to greatly reduce the cost barriers associated with MAT. The
recent vote in Maine to expand Medicaid has the potential to reduce the financial barriers associated
with MAT and can improve access to treatment for thousands of individuals with OUD in the state.
Nationally, states that have expanded Medicaid have seen the largest increases in treatment for
substance use disorders including a large increase in the provision of MAT.53
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Treatment Options: Treatment needs vary by individual and population characteristics. Traditional
treatment modalities may act as a deterrent for some individuals with OUD. Patients repeatedly
mentioned the need for a continuum of treatment services that address the unique needs of the
individuals seeking care. For example, one factor repeatedly mentioned by women is the need for
treatment programs that provide on-site child care or have policies that allow women to have regular
interactions with their children while they are in care. In addition, numerous individuals discussed the
need for treatment models that provide services at a centralized location where individuals can access
comprehensive MAT, primary care and psychosocial services. Patients indicated that “one-stop-shops”
help reduce transportation burdens, help with care coordination, and ease some of the time constraints
associated with addressing their complex
medical needs. Numerous patients also
“It's not reasonable to expect someone with a full time job
indicated that there is a need to
to be able to access a treatment program that requires a
implement models of care that offer a
continuum of services with varying multiple hours per week commitment. Nor can many of my
requirements and levels of intensity, i.e. patients afford to pay inordinate sums of money for their
programmatic options with services that treatment AND their prescription medication.”
-MAT Provider
correspond with individual treatment
needs at different stages of treatment,
maintenance, and recovery.
Provider Supports: Research
indicates that greater integration
of MAT for individuals with OUD in
primary care settings across Maine
would expand access to treatment
for hundreds of individuals living
in rural communities throughout
the state.54 Although models for
integrating MAT in primary care
vary in how they are structured, it
is clear that in order to effectively
recruit and engage providers in
the delivery of MAT, organizations
need to provide the necessary
resources and supports to
facilitate integration. Providers
consistently noted four key
components that are paramount to implementing MAT models in primary care: (1) organizational buyin and supports; (2) education/training and other resources for prescribing providers; (3) mechanisms
for coordination/integration of OUD treatment with other medical/psychological needs; and (4)
engagement of a broad group of stakeholders (see Necessary programmatic components for MAT
infographic above). Providers indicated that they were reluctant to deliver MAT if they did not feel they
had the necessary infrastructure to support implementation.
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Supporting Ongoing Recovery for Individuals with OUD
Quick access to treatment programs, consistent access to MAT, insurance coverage, auxiliary recovery
supports (e.g. transportation, safe and stable housing), peer and family support (e.g. group support
meetings, supportive families/friends, a peer recovery coach), as well as opportunities for community
integration (e.g. social activities and employment), were the most frequently mentioned factors
necessary to support ongoing maintenance and recovery (see Patient and Provider Perspectives:
Facilitators of Ongoing Recovery infographic below). One of the greatest challenges associated with
long-term maintenance for patients is the cost associated with MAT services, particularly for individuals
without insurance. As discussed earlier, even individuals with insurance face cost barriers as many public
and private insurance companies do not fully cover or pay for buprenorphine prescriptions.
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IV. Addiction Care Program Milestones
Year One Milestones
Although MeHAF’s Addiction Care Program is still in the early stages of implementation, grantee
activities have already increased statewide capacity for addressing the opioid epidemic by providing
training/education to providers, engaging a broad range of stakeholders in planning and
implementation activities, and expanding access to MAT services in primary care settings.
Training and Education: During the first year of the grant, Addiction Care Program grantee
organizations reported holding 320 training/education sessions covering a broad range of relevant
topics (Figure 4). Grantee organizations engaged in a large effort to provide training and education to
a broad group of stakeholders including executives, providers, administrative staff, and community
partners. On average, trainings lasted one to two hours and a total of 3,007 attendees were recorded
across the education and training sessions held by grantee organizations. Sessions covered a wide
variety of service delivery and implementation topics such as OUD screening and diagnosis, chronic pain
management, implementing MAT workflows, and patient engagement strategies. A total of 56
individuals received training in MAT. Twenty-five of these individuals went on to complete the required
federal training program necessary to prescribe or dispense buprenorphine, greatly increasing the
capacity of Addiction Care Program grantee organizations to deliver MAT in their targeted geographic
areas.
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Stakeholder Engagement: Creating sustainable, effective linkages between clinical and community
settings can improve patients' access to prevention, treatment and chronic care services by fostering
partnerships between clinical providers, community organizations, and public health agencies.55
Therefore, engaging a broad network of partners has been fundamental to the work of the Addiction
Care grantee organizations. Over the past year, program participants have formed partnerships and
collaborated with a broad range of stakeholders from a variety of sectors. The Stakeholder Engagement
Map shows that grantees most frequently interact with health care or community organizations and that
grantees have a diverse set of stakeholders on their committees and subcommittees.

Comprehensive cross-sector partnerships between health care, first responders, law enforcement,
business, peer recovery and social service agencies, are essential to increasing clinical-community
linkages, expanding low barrier access to treatment, reducing stigma, and creating recovery ready
communities. The clinical-community linkages grantee organizations have fostered over the past year
have played a critical role in helping programs establish the partnerships and infrastructure necessary
to create sustainable community systems of care for individuals in treatment and recovery.
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Capacity Building: The comprehensive planning and implementation activities of grantee organizations
have increased their organizational capacity and ability to effectively deliver MAT in primary care
settings. Between April and November of
2017, the number of providers delivering
MAT across the six implementation
grantee organizations nearly tripled from
27 providers to 73. This represents a 170%
increase in the number of prescribers
(Figure 5).
There was a corresponding increase in the
number of patients receiving MAT services
at program sites. Between October and
March there was a 75% increase in the
number of patients receiving MAT (Figure
6) and a 20% increase in the number of
patients with a documented diagnosis of
OUD
at
grantee
organizations.
Correspondingly, the number of MAT
patients increased by 15 percentage points
on average across grantee organizations.
Eighty percent of the individuals referred
for MAT services were assessed and
induced on buprenorphine (Figure 7),
indicating that grantee organizations were
successfully communicating with and
retaining patients as they enrolled in
treatment. Between October and March of
2017, 230 patients were referred for induction at 5 out of the 6 implementation sites. Research indicates
that retention rates for MAT can range from 56-90% and long-term abstinence rates range from 6170%.56 The high rate of initial induction
indicates that Addiction Care Program
grantee organizations have established
processes to efficiently screen, refer and
engage the majority of patients
appropriate for MAT into their programs.
Research indicates that individuals who are
induced and maintained in MAT programs
have significantly higher rates of treatment
adherence when compared to non-drug
approaches.
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This increases the chances a person will remain in treatment to learn the skills and build the networks
necessary to achieve long-term recovery and the associated positive social outcomes (i.e. stable
housing, employment, decreased interaction with criminal justice system).57 In addition to increasing
the number of patients seen and induced, sites also significantly increased the number of behavioral
health referrals at their sites. Between October and March, rates of patients referred to behavioral health
services continued to increase. Of the 937 patients who were referred to behavioral health services, 94%
attended their first behavioral health visit.
As evidenced by the data presented above, despite the numerous challenges associated with
implementing MAT in primary care settings, grantee organizations have made great strides in
establishing and/or expanding their organizational capacity to deliver MAT. Over the past year grantee
organizations have significantly enhanced provider capacity throughout the state to deliver MAT
through training and infrastructure development; increased access to MAT by expanding services in
rural and under-resourced communities; reduced wait-times between referral and induction; and
increased the number of patients receiving MAT (Figure 7). In addition, grantee organizations have
established clinical-community linkages between collaborating organizations which has led to increased
care coordination and patient engagement in both MAT and behavioral health services.

V.

Lessons Learned

Successful Strategies: Administrative and provider interview data collected over the course of the first
year of the Addiction Care Program provides key insights into the successful planning and
implementation strategies used by grantee organizations. The Successful Grantee Strategies graphic
captures the most commonly reported strategies that have successfully increased the capacity of both
planning and implementation grantee organizations to provide MAT services in primary care settings.
Grantee organizations indicated that collaboration and stakeholder engagement have been critical to
informing systems of care and establishing the partnerships necessary to provide comprehensive MAT
programs that include treatment, social services, and recovery supports. Both providers and patients
indicated that the provision of MAT services in environments that are co-located with physical and
behavioral health care greatly reduces barriers to access and facilitates a holistic approach to addressing
the complex physical and behavioral health care needs of individuals with OUD. Grantee organizations
who do not have a centralized treatment location have employed universal releases to increase low
barrier access to treatment while at the same time providing for improved communication and care
coordination across partner agencies. Additionally, the training and education activities undertaken by
grantee organizations have increased provider confidence and reduced stigma related to the delivery
of MAT. As a result, the number of providers delivering MAT at grantee organizations has significantly
increased in the past year. Finally, grantee organizations have worked to establish robust peer recovery
networks that are being leveraged to assist patients with a variety of auxiliary recovery supports.
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Challenges and Opportunities for Change: Over the course of the first year of the Addiction Care
Program, grantee organizations identified a number of challenges to expanding access to MAT in
primary care settings. Below is a brief summary of the primary obstacles identified by sites.
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Collaboration: Although Addiction Care Program grantee organizations have made significant
strides in establishing and maintaining the collaborative partnerships necessary to create
comprehensive systems of care for individuals with OUD, there remain challenges with managing
and sustaining cross-site, multi-sector collaboration among participating partners including:
competing priorities, maintaining meaningful engagement, and ensuring regular, open
communication. As most grantee organizations are using grant funding for this partnership
work, future sustainability of these collaborative efforts (once grant funding ends) is precarious;
in most cases there is no natural owner for this endeavor. Partnership work is critical to
establishing and sustaining the infrastructure necessary to expand access to MAT for OUD and
must continue to be supported to ensure the long-term viability of primary care- based MAT
programs.



Regulations: Several sites continue to face external regulatory hurdles that have impacted their
ability to expand or offer MAT and behavioral health services. For example, sites reported staff
members that were willing and able to join the MAT program were unable to obtain permanent
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licensure from the State of Maine. MaineCare’s prior authorization process was also identified
as a major hurdle and time burden by providers.

v



Staffing: Staff turnover and provider shortages continue to hinder MAT implementation and
expansion opportunities for grantee organizations. Staff turnover directly affected provider
capacity and impeded scheduling and/or meeting behavioral health counseling needs for 40%
of the grantee organizations in Year 1. All grantee organizations reported expanding provider
capacity as a priority in Year 2.



Stakeholder Engagement: One of MeHAF’s core values is that their efforts are guided by the
voices of the people they are dedicated to serve. The Addiction Care Program is dedicated to
creating and/or improving services that are patient-centered. To that end, all of the grantee
organizations continue to seek meaningful engagement of a diverse group of patients in
planning and implementation activities. Some grantee organizations struggled with identifying
and engaging patients throughout the first half of Year 1, but made strides in fostering
meaningful patient engagement as their programs developed. Grantee organization staff
reported the need to build trust with patients, which takes time, and the fact that patients are
often working or busy during the times when meetings are held or when they are seeking inperson feedback. Grantee organizations that were able to get patients and persons living in
recovery “to the table” for stakeholder meetings, reported the need to continue to sustain
meaningful engagement with their patients to continue to be responsive to their needs, not
just throughout the duration of the grant but as a model for the program’s future.



Referral Processes: A majority of grantee organizations would like to improve their
collaborations and referrals across patient entry points – Hub sites, Emergency Departments,
Behavioral Health, Psychiatry, PCPs, etc. Grantee organizations cite a “no wrong door” approach
as the goal and are working collaboratively with their partners to provide low barrier access to
MAT for patients.



Recovery Supports: Grantee organizations reported challenges in building a recovery network
with robust peer supports, something that is seen by providers and patients as a necessary
component for long-term maintenance and recovery from OUD. Many grantee organizations
have established relationships with recovery coaches and organizations, and are committed to
working with their key stakeholders to devise strategies that effectively develop, implement
and/or expand dynamic peer supports within their recovery networks.



Data Tracking and Monitoring: Ongoing data tracking and monitoring is essential for
monitoring clinical outcomes and tracking the progress of quality improvement activities within
a health care organization. Grantee organizations have experienced challenges in collecting and
reporting dashboard data in Year 1.v Initial challenges included narrowing down metrics and
ensuring all stakeholders were in agreement with which metrics were the most salient to their
respective project’s work. Because success looks different not only to each grantee, but to each
stakeholder within a grantee’s project, choosing metrics that capture and inform
accomplishments and challenges within a project are an ongoing refinement process for
grantee organizations and stakeholders. Current challenges include time (collecting, compiling,

In health care systems, data dashboards are frequently used to manage and track healthcare information, CQI metrics and other
essential measures to monitor programmatic performance and patient outcomes.
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and recording data; gathering and compiling data from multiple partners), technology (pulling
data from disparate electronic medical records (EMRs); reporting not set up in EMR; using a mix
of data collection methods), and staffing (allocating staff time for monitoring data; training).
Despite the noted challenges, many grantee organizations are actively working to streamline
data collection through new workflows and EMR updates.

Implications and Future Sustainability:
Data from Year 1 grantee activities provide implications for future activities and program sustainability.
There are a number of opportunities for future efforts focused on sustaining the new capacity and
expansion of MAT in Maine. A summary of future directions is provided below.
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Payment/Reimbursement for Services: It is evident that one of the greatest barriers to
implementing and sustaining MAT programs in primary care is resources. Practices often lack
the necessary financial resources as well as the human capital and organizational capacity to
expand and/or sustain MAT programs without external support and funding. In Maine, practices
still face great challenges meeting the eligibility requirements for the States’ Opioid Health
Home programs, which are specifically designed to provide financial resources to support MAT
and care coordination for complex uninsured and under-insured patients. (See Page 14. for
Opioid Health Home program descriptions.) Moreover, there remain challenges with adequate
reimbursement for MAT services and care coordination from federal and state resources. It is
evident that there continues to be a need to advocate for financial and technical resources to
make these programs accessible to practices and providers.



Low Barrier Access to Treatment: Research indicates that 80% of individuals with OUD do not
receive treatment; therefore, creating low barrier access to MAT is a critical component to
ensuring treatment initiation and engagement.58 Effective systems must ensure that individuals
with OUD needing treatment will be identified, assessed, and receive treatment, either directly
or through appropriate referral, no matter where he or she enters the realm of services.59 The
focus on creating “no wrong door” policies is imperative to developing delivery systems that
ensure access to treatment can be obtained through multiple pathways and from a variety of
sectors including: health care facilities, homeless shelters, social service agencies, emergency
departments, or criminal justice settings. Establishing clinical-community linkages is essential for
referral, assessment and treatment programs and policies that are consistent with a “no wrong
door” policy. Grantee organizations need to continue to work towards developing the interagency partnerships that promote low barrier access to MAT and provide the coordination
necessary to establish overall systems of care in their communities that are seamless and provide
continuity of care across service systems.



Patient-Centered Approach: There is a continued need for grantee organizations to focus on
creating treatment protocols and policies that include interventions specific to the tasks and
challenges faced by patients at each stage of treatment, maintenance and recovery. Our findings
indicate a need for MAT programmatic policies that facilitate engagement and the achievement
of treatment goals. Both providers and patients indicated that long-standing rigid treatment
program requirements (established separately from the Addiction Care Program) often make
long-term engagement difficult and can even create barriers to patients achieving desired
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treatment outcomes. It will be important for grantee organizations to regularly assess patient
feedback and utilize that information to refine program requirements to meet the unique needs
of participants and reinforce long-term participation in maintenance and recovery activities.
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Information for Patients and Families: While creating the infrastructure to support MAT in
primary care practices is paramount, awareness of OUD, available treatment options, and
community supports for individuals and families affected by substance use disorder remains a
challenge, particularly in rural communities. Many patients and providers discussed the need for
more comprehensive communication strategies to effectively share information about available
recovery and MAT-specific services in their communities. In addition, patients repeatedly
discussed a need for more awareness, messaging aimed at reducing stigma, and education for
the community about OUD and the effectiveness of using MAT to address OUD. Future MeHAF
efforts could include working with grantee organizations on their communications plans and
public awareness outreach within the communities they serve.



Auxiliary Recovery Supports: Patients and providers agreed that auxiliary recovery supports
including safe housing, food security, and transportation are crucial elements of patient recovery.
Although grantee organizations have made strides in facilitating care coordination and
establishing relationships with recovery supports, many noted difficulties in establishing the
infrastructure necessary to assist patients with the recovery supports necessary to facilitate
effective treatment engagement and long-term recovery. Future efforts could include building
models of care with embedded patient navigators in the system who can guide individuals
through the process of treatment initiation and ongoing engagement, while at the same time
providing assistance with transportation and the hierarchy of recovery supports needed by a
person living in recovery (employment, housing, etc.).



Peer Support for MAT Providers: Providers agree that MAT prescribers could benefit from
professional mentoring, particularly providers that have recently completed X-waiver training.
Some Addiction Care Program grantees report having ad-hoc, informal mentoring within their
staff structure and workflows. Whether or not this peer support for providers is happening within
an organization, most providers agree that a more formal MAT provider-to-provider network or
clearinghouse would be beneficial for further training and information sharing. Future
opportunities could harness the natural connection across these grantee organizations to create
such a network.



Overdose Prevention: Given the high rates of overdoses in the state, there appears to be a need
for grantee organizations to leverage their current clinical-community linkages and cross-sector
collaboration to expand access to Overdose Prevention Education and Naloxone Distribution
(OPEND) programs. Of high importance is developing and implementing screening protocols
that identify patients at high risk for overdose and in need of overdose prevention education. In
addition, expanded access to naloxone for high risk patients and linking them to harm reduction
and MAT services are key elements to addressing opioid related morbidity and mortality.



Systems to Monitor Patient Panels: While data dashboards were developed to assist sites with
data tracking and provide rapid cycle feedback on program strategies through continuous
quality improvement measures (CQI), collecting valuable data on patient induction, stabilization
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and maintenance remains a struggle for many grantee organizations whose electronic medical
records do not allow for easy tracking or extraction of this data. Finding strategies to help
grantee organizations implement systems for ongoing monitoring of OUD patient panels will be
critical to expanding practice and provider capacity for delivery of MAT.

VI.

Limitations

There are several limitations to the data collected in this report. The first limitation of this evaluation is
that grantee organizations selected who would be surveyed, interviewed, and/or participate in a focus
group. As a result, some sites opted to electronically distribute surveys to a larger audience than others
and therefore their results may not be parallel to sites that only surveyed those who were planning to
be directly involved in the program. Providers who filled out surveys may not have been offered the
opportunity to participate in interviews and providers who participated in interviews may have been
more motivated to participate due to their existing engagement with MAT. An additional limitation of
the data is the reliance on site-reported data (i.e. dashboard data) which is limited by the fact that
despite built in quality checks, the data cannot be completely and independently verified. Therefore,
dashboard data is subject to self-report biases, including over or under reporting. Lastly, we were unable
to interview providers from all ten sites or engage patients in focus groups from all ten sites due to
logistics (e.g. weather, busy practices) and patient barriers (e.g. transportation, time commitment,
interest). Data collected and analyzed for this evaluation may not be generalizable to other programs
with similar goals in Maine and elsewhere; however the results do provide valuable information on
implementation processes and outcomes that can be used to help inform effective strategies for
overcoming barriers to delivering MAT in primary care practices.

VII. Next Steps
Moving into the second year of the grant, Addiction Care Program grantee organizations will build on
their efforts in the first year of the program by continuing to refine referral and intake processes as they
work with both internal resources and external partners. They will work towards implementing or
finalizing standard treatment protocols and care plans for MAT patients and continuing ongoing
collaborations with existing or new community partners. Education and training of providers remains a
priority for grantee organizations and they will continue to sponsor or engage in relevant professional
development and outreach activities. In addition, grantee organizations remain dedicated to the
participation and contribution of persons living in recovery. Finding meaningful opportunities to engage
stakeholders in recovery remains a top priority for grantee organizations.
Planning Grantee Organizations: The planning grantee organizations, in particular, have indicated that
operationalizing their referral process, practice protocols and increasing staff capacity are tantamount
to achieving their goals in Year 2. As planning grantee organizations move into the implementation
phase of their projects, they will focus on implementing the infrastructure necessary to support new
processes and workflows within their programs. Planning grantee organizations’ timelines for piloting
MAT services vary, but will all take place before the completion of the grant program in April 2019, as a
requirement of the grant.
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York Hospital began accepting patients in April 2018 with the goal to have capacity for up to
160 new MAT patients by March 31, 2019.
Tri-County Mental Health Services plans to begin their pilot in August 2018.
Kennebec Behavioral Health plans to begin their pilot in December 2018.
LincolnHealth is expanding their existing MAT network with plans for up to ten new patients
in their Damariscotta location between January – March 2019.

Implementation Grantee Organizations: The implementation grantee organizations will continue
refining their workflows and referrals processes in Year 2 as they expand their MAT services. Several
grantee organizations’ “hub and spoke” models will be facilitating collaboration between the “hub” and
the primary care offices “spokes” that will be expanding or implementing MAT services.
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MaineGeneral will be training new providers to deliver MAT in six targeted MaineGeneral
primary care practices or within their current onsite stabilization program — Outpatient Plus
(OPP), tracking provider capacity by primary care location, increasing capacity of behavioral
health integrated care specialists, and expanding OPP into Waterville by January-March 2019.
Healthy Acadia is currently launching its treatment hub (Down East Treatment Center) which
will include intake of new patients. Over the summer of 2018 they will be educating and training
the current spoke sites as they begin preparing new PCP sites for comprehensive MAT delivery
during the next year, and will continue to coordinate, assess, and modify their robust Peer
Recovery Support System.
Healthy Community Coalition will be focused on increasing MAT provider capacity with
trainings and establishing an MAT provider peer community, expanding MAT in both primary
care as well as clinical (i.e., OB/GYN) settings, and mapping capacity in greater Franklin and
Oxford counties to create a treatment approach algorithm that will link all treatment services in
greater Franklin County.
Health Access Network will continue provider trainings for clinical staff as well as training all
front line staff (reception, MAs) on protocols for MAT in tandem with education for recovery
coaches within the community. Their minimum patient panel goal is to have capacity for 40-45
patients at all times and to increase capacity to 90 patients within the first three years of an
established program.
Amistad will continue working within the Greater Portland Addiction Collaborative (GPAC) to
build primary care capacity for comprehensive MAT, as they optimize referral processes and
create a compassionate tapering protocol across their partner organizations. Specific to their
recovery residence, a major aspect of expanding their patient-centered care is to have the
women in the house take on leadership roles within the project, receive training so they can
facilitate groups and provide peer supports and navigation for others enrolling into MAT.
Penobscot Community Health Care intends to increase the number of PCHC providers
delivering MAT from 25 to 31, increasing capacity for the number of patients from all sources
from 400 to 650. They will continue to train providers, through peer-to-peer mentorship among
clinical staff, as they implement broader coordination of social services necessary for patients to
achieve and sustain recovery.
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VIII. Summary
Maine is among the states hardest hit by a national trend of non-medical uses of opioid prescription
drugs and increasing use of heroin, with subsequent increases in opioid-related morbidity and mortality.
Addressing the opioid epidemic in Maine is particularly challenging given the rural nature of the state.
Despite ongoing state and local efforts to improve access to treatment services for individuals with OUD,
promote awareness of the opioid epidemic and foster safe prescribing of opioid prescription drugs,
rates of opioid related overdoses and deaths continue to rise. MeHAF’s Addiction Care Program is
addressing crucial access gaps in treatment infrastructure, provider training/education, and
organizational capacity to deliver MAT in primary care settings. During the first year of the program,
grantee organizations significantly expanded their capacity to deliver MAT in primary care settings as
evidenced by the number of new prescribers and the increase in the number of patients served. As
grantee organizations move into the second year of the program, they will continue to pilot innovative
strategies that address barriers to expanding access to MAT in Maine communities.
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